PMP22 Gene Expression and Breast Cancer Survival
Author Information
Author(s): Tong Dan, Heinze Georg, Pils Dietmar, Wolf Andrea, Singer Christian F, Concin Nicole, Hofstetter Gerda, Schiebel Ingrid, Rudas Margaretha, Zeillinger Robert
Primary Institution: Medical University of Vienna
Hypothesis
The expression of PMP22 and epithelial membrane proteins can have prognostic impacts on breast cancer.
Conclusion
PMP22 gene expression is a novel independent prognostic factor for disease-free survival and overall survival for breast cancer patients.
Supporting Evidence
- Patients with higher than median PMP22 gene expression have a 3.47 times higher risk to die of cancer.
- Patients with higher than median PMP22 gene expression have a 1.77 times higher risk to relapse.
- PMP22 contributes equally to prognosis of overall survival as nodal status and estrogen receptor status.
- The proportion of explained variation in overall survival due to PMP22 gene expression was 6.5%.
- Cross validation demonstrates that 5-years survival rates can be refined by incorporating PMP22 into the prediction model.
Takeaway
If a breast cancer patient has high levels of a certain gene called PMP22, they are more likely to have a worse outcome than those with lower levels.
Methodology
Gene expression of PMP22 and EMPs was measured in 249 primary breast tumors by real-time PCR and analyzed statistically.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the reliance on existing clinical data.
Limitations
The study is retrospective and may have biases related to the selection of patients and data collection.
Participant Demographics
Patients aged 27 to 89 years, with a mean age of 58 and a median age of 57 at diagnosis.
Statistical Information
P-Value
0.0002
Confidence Interval
1.82 - 6.62
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website